137 related articles for article (PubMed ID: 11944781)
1. Combined calcitriol-pamidronate therapy for bone hyperresorption in spinal cord injury.
Chen B; Mechanick JI; Nierman DM; Stein A
J Spinal Cord Med; 2001; 24(4):235-40. PubMed ID: 11944781
[TBL] [Abstract][Full Text] [Related]
2. Effect of a convenient single 90-mg pamidronate dose on biochemical markers of bone metabolism in patients with acute spinal cord injury.
Mechanick JI; Liu K; Nierman DM; Stein A
J Spinal Cord Med; 2006; 29(4):406-12. PubMed ID: 17044392
[TBL] [Abstract][Full Text] [Related]
3. Biochemical response to treatment of bone hyperresorption in chronically critically ill patients.
Nierman DM; Mechanick JI
Chest; 2000 Sep; 118(3):761-6. PubMed ID: 10988200
[TBL] [Abstract][Full Text] [Related]
4. Intravenous pamidronate attenuates bone density loss after acute spinal cord injury.
Nance PW; Schryvers O; Leslie W; Ludwig S; Krahn J; Uebelhart D
Arch Phys Med Rehabil; 1999 Mar; 80(3):243-51. PubMed ID: 10084430
[TBL] [Abstract][Full Text] [Related]
5. Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover.
Rosen HN; Dresner-Pollak R; Moses AC; Rosenblatt M; Zeind AJ; Clemens JD; Greenspan SL
Calcif Tissue Int; 1994 Jan; 54(1):26-9. PubMed ID: 8118749
[TBL] [Abstract][Full Text] [Related]
6. Short-term calcitriol administration improves calcium homeostasis in adults with cystic fibrosis.
Brown SA; Ontjes DA; Lester GE; Lark RK; Hensler MB; Blackwood AD; Caminiti MJ; Backlund DC; Aris RM
Osteoporos Int; 2003 Jun; 14(5):442-9. PubMed ID: 12774194
[TBL] [Abstract][Full Text] [Related]
7. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
[TBL] [Abstract][Full Text] [Related]
8. Prevention of appendicular bone loss in Paget's disease following treatment with intravenous pamidronate disodium.
Stewart GO; Gutteridge DH; Price RI; Ward L; Retallack RW; Prince RL; Stuckey BG; Kent GN; Bhagat CI; Dhaliwal SS
Bone; 1999 Feb; 24(2):139-44. PubMed ID: 9951784
[TBL] [Abstract][Full Text] [Related]
9. Bone hyperresorption is prevalent in chronically critically ill patients.
Nierman DM; Mechanick JI
Chest; 1998 Oct; 114(4):1122-8. PubMed ID: 9792587
[TBL] [Abstract][Full Text] [Related]
10. Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men.
Leder BZ; Smith MR; Fallon MA; Lee ML; Finkelstein JS
J Clin Endocrinol Metab; 2001 Feb; 86(2):511-6. PubMed ID: 11158001
[TBL] [Abstract][Full Text] [Related]
11. Effects of pamidronate and calcitriol on the set point of the parathyroid gland in postmenopausal hemodialysis patients with secondary hyperparathyroidism.
Huang CY; Zheng CM; Wu CC; Lo L; Lu KC; Chu P
Nephron Clin Pract; 2012; 122(3-4):93-101. PubMed ID: 23635416
[TBL] [Abstract][Full Text] [Related]
12. Metabolic effects of single-dose pamidronate administration in prostate cancer patients with bone metastases.
Berruti A; Dogliotti L; Tucci M; Tarabuzzi R; Guercio S; Torta M; Tampellini M; Dovio A; Poggio M; Scarpa RM; Angeli A
Int J Biol Markers; 2002; 17(4):244-52. PubMed ID: 12521128
[TBL] [Abstract][Full Text] [Related]
13. Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment.
Chapurlat RD; Hugueny P; Delmas PD; Meunier PJ
Bone; 2004 Jul; 35(1):235-42. PubMed ID: 15207763
[TBL] [Abstract][Full Text] [Related]
14. Prevention of bone loss after heart transplantation with antiresorptive therapy: a pilot study.
Shane E; Rodino MA; McMahon DJ; Addesso V; Staron RB; Seibel MJ; Mancini D; Michler RE; Lo SH
J Heart Lung Transplant; 1998 Nov; 17(11):1089-96. PubMed ID: 9855448
[TBL] [Abstract][Full Text] [Related]
15. Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma.
Terpos E; Palermos J; Tsionos K; Anargyrou K; Viniou N; Papassavas P; Meletis J; Yataganas X
Eur J Haematol; 2000 Nov; 65(5):331-6. PubMed ID: 11092464
[TBL] [Abstract][Full Text] [Related]
16. Effect of pamidronate on excretion of pyridinium crosslinks of collagen after total hip arthroplasty.
Wilkinson JM; Jackson B; Eastell R
Calcif Tissue Int; 2003 Oct; 73(4):326-31. PubMed ID: 12874697
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy.
Vinholes J; Guo CY; Purohit OP; Eastell R; Coleman RE
J Clin Oncol; 1997 Jan; 15(1):131-8. PubMed ID: 8996134
[TBL] [Abstract][Full Text] [Related]
18. Effects of calcitriol on parathyroid function and on bone remodelling in secondary hyperparathyroidism.
Costa AF; dos Reis LM; Ribeiro MC; Moysés RM; Jorgetti V
Nephrol Dial Transplant; 2003 Apr; 18(4):743-9. PubMed ID: 12637644
[TBL] [Abstract][Full Text] [Related]
19. Pamidronate and biochemical markers of bone turnover.
Martínez ME; Del Campo MT; Plaza MA; Torrijos A; Gijón J
Scand J Clin Lab Invest; 1997 Nov; 57(7):581-6. PubMed ID: 9397488
[TBL] [Abstract][Full Text] [Related]
20. A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease.
Bartram SA; Peaston RT; Rawlings DJ; Francis RM; Thompson NP
Aliment Pharmacol Ther; 2003 Dec; 18(11-12):1121-7. PubMed ID: 14653832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
